Stifel Nicolaus Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

Insmed (NASDAQ:INSM) had its price objective raised by Stifel Nicolaus from $205.00 to $208.00 in a report published on Tuesday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on INSM. Wells Fargo & Company lowered their price target on shares of Insmed from $208.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday. Bank of America boosted their price objective on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday. TD Cowen set a $241.00 target price on Insmed in a research report on Thursday, December 18th. Morgan Stanley set a $166.00 target price on Insmed in a research note on Friday, February 20th. Finally, Leerink Partners reissued an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Insmed currently has a consensus rating of “Buy” and an average target price of $209.38.

Insmed Price Performance

NASDAQ:INSM opened at $139.14 on Tuesday. Insmed has a one year low of $60.40 and a one year high of $212.75. The company has a market cap of $29.99 billion, a P/E ratio of -21.71 and a beta of 1.13. The firm’s fifty day moving average price is $150.99 and its two-hundred day moving average price is $166.23. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The company had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. Insmed’s revenue for the quarter was up 152.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.32) earnings per share. Equities analysts expect that Insmed will post -4.56 earnings per share for the current year.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $143.52, for a total transaction of $1,535,520.48. Following the transaction, the chief executive officer directly owned 301,185 shares of the company’s stock, valued at approximately $43,226,071.20. This trade represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael Alexander Smith sold 640 shares of Insmed stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $156.27, for a total transaction of $100,012.80. Following the completion of the sale, the insider owned 56,397 shares of the company’s stock, valued at approximately $8,813,159.19. The trade was a 1.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 189,651 shares of company stock worth $31,533,654 over the last quarter. Company insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

A number of hedge funds have recently added to or reduced their stakes in INSM. Vanguard Group Inc. boosted its holdings in shares of Insmed by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after purchasing an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. raised its holdings in shares of Insmed by 2.3% during the 4th quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after buying an additional 475,832 shares in the last quarter. Capital International Investors lifted its position in shares of Insmed by 1.0% during the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after buying an additional 74,994 shares during the last quarter. State Street Corp lifted its position in shares of Insmed by 30.6% during the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after buying an additional 1,217,390 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its stake in Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after buying an additional 1,623,342 shares in the last quarter.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Positive Phase 3b ENCORE topline results for ARIKAYCE support label expansion and larger market opportunity; Insmed plans to file a supplemental NDA with the FDA and submit data to Japan’s PMDA in H2 2026. This is the primary fundamental catalyst behind recent upside for the shares. PR Newswire: ENCORE topline
• Positive Sentiment: Multiple brokerages raised price targets (Leerink to $215, Bank of America to $213, Stifel to $208), signaling analyst confidence and implying ~50%+ upside from current levels — providing buy-side support. Benzinga: price target updates
• Positive Sentiment: Analyst commentary and coverage (including a Seeking Alpha “Strong Buy” piece) frame the ENCORE data as a material commercial opportunity — potential first-line MAC label expansion, conversion of accelerated approval and additional international upside. Seeking Alpha: Strong Buy
• Neutral Sentiment: Widespread media coverage (Zacks, MarketWatch, CNBC, Stat/others) amplified the clinical news and drove intraday momentum; these reports support short-term volatility but are secondary to the underlying trial outcome. Zacks: Arikayce hits goal
• Neutral Sentiment: Short-interest reports in the feed show large increases but the published figures read as 0/NaN and inconsistent across sources — the data appears unreliable and should not be treated as confirmed short‑squeeze signal.
• Negative Sentiment: Insider selling: the CEO sold roughly $1.54M of stock, which can raise governance/near‑term sentiment concerns even when filings show routine sales. AmericanBankingNews: Insider sale
• Negative Sentiment: Wells Fargo trimmed its price target to $175 (still “overweight”) — a relative cut vs. other firms that may have contributed to profit‑taking and intraday weakness.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.